A variety of factors, such as low COVID-19 vaccination rates and Americans’ general poor health, is behind the life expectancy drop, experts say.
Author: Karen Weintraub, USA TODAY
COVID-19 is about to explode in China. What that could mean for the United States.
Experts are predicting COVID cases in China will explode after the country ended its strict zero-COVID policy. Here’s how the US may be affected.
An end to chronic pain? Future treatment could look very different.
Over the next decade or more experts say pain treatment will look very different than it does today, with more effective care.
America has a pain problem. How can we find relief?
To better understand America’s pain problem and what to do about it, USA TODAY spoke with more than 50 pain experts and people with chronic pain.
NFL players age faster than the rest of us. Harvard is researching what can be done.
A Harvard study finds NFL players age a decade faster than the general population and are suffering young from arthritis and high blood pressure.
Weight loss treatment is on the verge of transformation. It’s not there yet. Here’s why.
New medicines like Wegovy promise dramatic weight loss, but there’s a long way to go to make anti-obesity drugs accessible to those who need them.
Where did mpox go? Here’s what brought down cases of disease formerly known as monkeypox.
Cases of the disease formerly known as monkeypox are down as the Biden administration declares an end to the public health emergency.
Stool tests like Cologuard are gaining popularity over colonoscopy. Which should you get?
Colonoscopy is recommended for people over 45, but preparation turns off many. Here’s a look at how it compares to stool tests FIT and Cologuard.
Sperm counts are decreasing, study finds. What might it mean for fertility?
Sperm counts have dropped globally, raising new questions about exposures, men’s health and what it could mean for fertility.
Thousands of babies and children are hospitalized by RSV every year. Why that could soon change.
Six drug companies are now developing RSV vaccines or antibodies, suggesting this year could be the last without adequate tools to fight the virus.